argenx SE (NASDAQ:ARGX) Shares Sold by CenterBook Partners LP

CenterBook Partners LP lessened its stake in argenx SE (NASDAQ:ARGX - Free Report) by 65.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,155 shares of the company's stock after selling 4,154 shares during the quarter. CenterBook Partners LP's holdings in argenx were worth $1,325,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of ARGX. Whipplewood Advisors LLC purchased a new stake in shares of argenx during the 4th quarter valued at about $37,000. Global Retirement Partners LLC boosted its stake in shares of argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after acquiring an additional 48 shares in the last quarter. FIL Ltd purchased a new stake in shares of argenx in the fourth quarter valued at $38,000. Jones Financial Companies Lllp lifted its position in argenx by 1,016.7% in the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after buying an additional 61 shares in the last quarter. Finally, Huntington National Bank lifted its stake in shares of argenx by 1,133.3% in the 4th quarter. Huntington National Bank now owns 74 shares of the company's stock valued at $46,000 after purchasing an additional 68 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company's stock.

Analysts Set New Price Targets

ARGX has been the topic of a number of research reports. Guggenheim boosted their target price on shares of argenx from $775.00 to $1,100.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. Wells Fargo & Company upped their target price on shares of argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. HC Wainwright reissued a "buy" rating and set a $720.00 price objective on shares of argenx in a research note on Tuesday, April 8th. JMP Securities increased their price objective on shares of argenx from $606.00 to $696.00 and gave the stock a "market outperform" rating in a research note on Tuesday, January 14th. Finally, Robert W. Baird increased their target price on argenx from $650.00 to $680.00 and gave the stock a "neutral" rating in a research note on Tuesday, March 4th. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $690.33.

Remove Ads

argenx Price Performance

ARGX stock traded down $13.01 during midday trading on Wednesday, hitting $592.37. 96,120 shares of the stock traded hands, compared to its average volume of 308,025. argenx SE has a 1-year low of $352.77 and a 1-year high of $678.21. The firm has a market cap of $35.99 billion, a P/E ratio of -673.15 and a beta of 0.60. The stock's fifty day simple moving average is $605.51 and its 200-day simple moving average is $604.95.

argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, research analysts predict that argenx SE will post 3.13 earnings per share for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.